The experimental drug daraxonrasib showed encouraging results in patients with advanced lung cancer. Tumors shrank in 37% of study participants, and in a separate group of patients who had previously received chemotherapy and immunotherapy, the figure was 42%.
The drug’s main feature is its ability to target several active forms of RAS proteins at once, which help tumor cells grow. Among patients who responded to treatment, the median time without disease progression was 8.3 months, and overall survival was 16 months.
The drug could become another treatment option for patients with advanced lung cancer, especially when previous therapy has not produced the desired result.
